Published on 15 May 2024 on GuruFocus.com via Yahoo Finance
Atossa Therapeutics Inc (ATOS) Q1 2024 Earnings: Aligns with Analyst Projections Amidst ...
Net Loss: Reported a net loss of $7.0 million for Q1 2024, slightly above the estimated net loss of $8.3 million.Revenue: Recorded no revenue for Q1 2024, consistent with analyst estimates of $0.00 million.Research and Development Expenses: Increased to $3.7 million in Q1 2024, up from $3.5 million in Q1 2023, driven by higher spending on clinical and non-clinical trials.General and Administrative Expenses: Decreased to $3.2 million in Q1 2024 from $3.6 million in Q1 2023, primarily due to lower non-cash stock-based compensation.Interest Income: Grew to $1.1 million in Q1 2024, up from $0.9 million in the previous year, attributed to higher yields from money market accounts.Cash Position: Ended Q1 2024 with a strong cash balance of $84.0 million, maintaining a robust financial position with no debt.
Warning! GuruFocus has detected 1 Warning Sign with ATOS.